Breast Cancer Clinical Trial
A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors
Summary
To assess the safety and tolerability at increasing dose levels of PF-06650808 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Eligibility Criteria
Inclusion Criteria:
Diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available
Previously treated metastatic triple negative breast cancer that expresses Notch3 with at least one measurable lesion
Adequate bone marrow, renal and liver function
Exclusion Criteria:
Major surgery, radiation therapy or systemic anti-cancer therapy within 4 weeks of starting study treatment
Patients with known symptomatic brain metastases requiring steroids
Prior treatment with a compound of the same mechanism
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 6 Locations for this study
Los Angeles California, 90095, United States
Los Angeles California, 90095, United States
Los Angeles California, 90095, United States
Los Angeles California, 90095, United States
Santa Monica California, 90404, United States
Santa Monica California, 90404, United States
Columbus Ohio, 43210, United States
Columbus Ohio, 43210, United States
Columbus Ohio, 43212, United States
Columbus Ohio, 43221, United States
San Antonio Texas, 78229, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.